Vaxcyte is seeking a highly motivated Staff Engineer to join the Protein Process Development and Manufacturing group supporting downstream purification, process development, technology transfer, process validation, GMP manufacturing support, and process lifecycle management.
This role is initially focused on technology transfer, manufacturing support, process validation, and commercialization activities for protein manufacturing processes. The successful candidate will partner closely with Contract Manufacturing Organizations (CMOs) and internal stakeholders to ensure successful transfer, scale-up, validation, and commercial execution of downstream purification processes.
The individual will serve as a recognized technical authority in downstream purification whose scientific expertise and engineering judgment influence program-level decisions across process development, technology transfer, validation, and commercial manufacturing. The successful candidate will provide leadership in solving complex technical challenges, developing innovative solutions, and guiding cross-functional teams through critical manufacturing and process development decisions.
As commercial manufacturing processes mature and transition into routine operation, this position is expected to evolve toward a broader Process Development role with increasing involvement in process optimization, next-generation process development, scale-down model development, process characterization, pilot-scale studies, and lifecycle process improvement. This provides a unique opportunity to work across the full product lifecycle, from development through commercial manufacturing and continuous process improvement, while helping shape the future downstream purification strategy for the Protein organization.
Essential Functions:
Requirements:
Reports to: Associate Director, MSAT (Protein Process Development and Manufacturing (Downstream)
Location: Onsite (San Carlos, CA)
Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy): Onsite - 4 days per week onsite
Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $186,000 – $218,000 (SF Bay Area).
Equal Opportunity
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
Recruitment Fraud Notice
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at vaxcyte.com/careers
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, our 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
We are re-engineering the way highly complex vaccines are made. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
In addition to our PCV franchise, our pipeline includes early-stage programs targeting Group A Strep, periodontitis and Shigella. At Vaxcyte, we are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
